[New agents developed for the treatment of benign prostatic hyperplasia].
Akakura
Koichiro
K
Department of Urology, Tokyo Kosei Nenkin Hospital.
D058891:5-alpha Reductase Inhibitors; D047072:Aromatase Inhibitors; D002986:Clinical Trials as Topic; D015195:Drug Design; D065128:Endothelin Receptor Antagonists; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators; D018120:Finasteride / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015221:Potassium Channels / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000209:etiology; D011743:Pyrimidines / Q000737:chemistry / Q000627:therapeutic use; D013449:Sulfonamides / Q000737:chemistry / Q000627:therapeutic use
D058891:5-alpha Reductase Inhibitors; D047072:Aromatase Inhibitors; D065128:Endothelin Receptor Antagonists; D004791:Enzyme Inhibitors; D020847:Estrogen Receptor Modulators; D015221:Potassium Channels; D011743:Pyrimidines; D013449:Sulfonamides; C113972:T 0201; D018120:Finasteride